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Associations of hypertension 
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Gregory Y. H. Lip3,5* & Boyoung Joung1,5*
In this nationwide cohort study, we assessed the effects of hypertension burden and blood pressure 
(BP) control on dementia in different age subgroups. From the Korean National Health Insurance 
Service‑Health Screening cohort from January 1, 2005 to December 31, 2013, we enrolled 428,976 
subjects aged 40–79 years without previous diagnosis of dementia or stroke. During a mean follow‑up 
of 7.3 ± 1.5 years, 9435 (2.2%) were diagnosed with dementia. Per 10 mmHg increase in systolic BP 
(SBP), risk of dementia was increased by 22% (95% confidence interval [CI] 1.15–1.30) in subjects 
aged 40–59 years and 8% (95% CI 1.04–1.11) in subjects aged 60–69 years. No significant associations 
were observed in subjects aged ≥ 70 years. Among subjects aged 40–59 years, both vascular and 
Alzheimer’s dementia risks were increased with increasing SBP. Increasing hypertension burden 
(proportion of days with increased BP) was associated with higher dementia risk (hazard ratio [HR] 
1.09 per 10% increase, 95% CI 1.08–1.10). Among patients with baseline SBP ≥ 140 mmHg, optimal 
follow‑up SBP (120–139 mmHg) was associated with decreased dementia risk (HR 0.69, 95% CI 
0.50–0.95). Hypertension burden was associated with higher risks of dementia. Adequate BP control 
was associated with lower risk of dementia in individuals aged < 70 years.
Dementia is characterized by a decline in memory, language, problem-solving and other cognitive skills that 
affects a person’s ability to perform everyday  activities1. Approximately 40 million people worldwide have demen-
tia, and this number is expected to increase up to 115 million by 2050 due to the aging  population2. To date, no 
proven interventions are available to prevent or delay dementia.
Hypertension, which affects more than 75% of people > 65 years of age, has emerged as a potential modifiable 
risk factor for mild cognitive impairment and dementia in observational  studies3. The relationship between blood 
pressure (BP) and dementia is well  established4. Persistent midlife hypertension is associated with increased risk 
of a late life  dementia5,6, leading it to be included as a putative risk factor in dementia prevention  guidelines4,7. 
However, in several randomized clinical trials (RCTs) about the effects of BP reductions on cognitive outcomes, 
including a recently published SPRINT MIND, results have generally been  inconclusive8–11. In systematic reviews, 
the association of hypertension with cognitive dysfunction and dementia has been suggested to differ based on 
age and follow-up duration and to contribute to lack of consensus. Therefore, to fully evaluate the association 
of hypertension and cognitive outcomes, evaluation of the age-specific effects of BP with a sufficiently long 
follow-up period is needed.
In the present nationwide, population-based study, we investigated the associations of systolic (SBP) and 
diastolic BP (DBP) level and hypertension burden with dementia risk in wide range of age subgroups. Moreover, 
we investigated whether BP control over time was associated with reduction of dementia risk.
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Methods
This study was based on the Korean National Health Insurance Service-Health Screening (NHIS-HealS) cohort 
released in  201512,13. The general health screening program can be applied at least once every 2 years for the entire 
population of Korean adults aged 40 years or  older14. The cohort consisted of 514,764 Koreans as an initial 2002 
cohort and followed subjects through 2013 on data including sociodemographic information, diagnoses based 
on the 10th revision of the International Classification of Disease-10 (ICD-10) codes, admission, treatment, 
and National Health Screening  data12,13. National Health Screening is conducted biennially and includes regular 
blood tests, chest X-rays, physical examinations, and medical history questionnaires. Information on death (date 
and cause) from Statistics Korea was individually linked using unique personal identification  numbers12,13. This 
study was approved by the Institutional Review Board of Yonsei University Health System (4-2014-0996), and 
informed consent was waived.
Study population. The first three years of the cohort (2002 ~ 2004) were set as the window period for 
obtaining baseline comorbidities and drug use of the study population. Therefore, 57,253 subjects who had 
undergone initial National Health screening between January 2002 to December 2004 were excluded from the 
initial study population. Subsequently, adults ≥ 40 years of age who underwent initial National Health screening 
between January 1, 2005 and December 31, 2013 (n = 457,511) were identified from the NHIS-HealS  cohort13. 
Subjects with the following were excluded: (i) BP not measured at initial health screening (n = 162); (ii) his-
tory of ischemic stroke or transient ischemic attack before initial health screening (n = 22694); (iii) history 
of hemorrhagic stroke before initial health screening (n = 1140); (iv) previous diagnosis of dementia at index 
date (n = 503); and (v) age ≥ 80 years (n = 4036). Finally, this study included 428,976 subjects (Fig. 1). The study 
index date was that of initial health screening. Prespecified age subgroups were as follows: 40–59, 60–69, and 
70–79 years.
BP measurement. BP measurements were performed at local hospitals and clinics certified as medical 
health examination centers by the Korean National Health Insurance  Corporation15–17. After ≥ 5 min of rest in 
the sitting position, BP was measured at the brachial artery by qualified medical personnel. Automatic oscil-
lometric devices or mercury sphygmomanometers were used, with the choice of device left to the discretion of 
individual examination centers. If the first BP measurement was > 120/80 mmHg, the measurement was repeated 
once to prevent  overestimation16,17. The main analysis used BP measured at the index date (initial health screen-
ing).
Comorbidities and outcomes. Baseline comorbidities were defined using the medical claims and pre-
scription medication prior to the index date. To ensure diagnostic accuracy, the participants were considered to 
have comorbidities when the condition was diagnosed at discharge or was confirmed at least twice in an outpa-
tient setting, similar to previous studies using the National Health Insurance Service (NHIS)  database13,16–18. The 
detailed definitions of comorbidities are presented in Supplementary Table 1.
The study endpoint was first occurrence of dementia, which was defined as dementia diagnosis combined 
with use of one or more of the following dementia drugs: rivastigmine, galantamine, memantine, or donepezil. 
457,511 Patients in the NHIS-HealS data who 
received initial health checkup during the period 
from January 1, 2005 to December 31, 2013
Excluded (n=28,535)
- Those who did not receive BP measurement at first 
health screening (n=162)
- Those who had an ischemic stroke or transient ischemic 
attack before initial health checkup (n=22,694)
- Those who had a hemorrhagic stroke before initial 
health checkup (n=1,140)
- Those who were ever diagnosed as dementia before 
first health screening (n=503)
- Patients aged ≥80 years (n=4,036)
60 ~ 69 years
(n =96,306)
428,976 patients with initial BP 
measurements
70 ~ 79 years
(n = 39,848)
40 ~ 59 years
(n =292,822)
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Participants were followed from the index date and censored at occurrence of dementia, death, or December 
31, 2013, whichever occurred first.
Use of prescription medication was ascertained by identifying database claims within 90 days before the 
index date. Income status was evaluated based on total amount of national health insurance premiums paid by 
the insured individual in the index year, which is proportional to the individual’s income.
The definitions of overall dementia, Alzheimer’s or vascular dementia were based on the recording of rel-
evant ICD-10 codes (F00 or G30 for Alzheimer’s disease; F01 for vascular dementia; and F02, F03, or G31 for 
other dementia) and the prescription of medication for dementia (rivastigmine, galantamine, memantine, or 
donepezil). When both codes for Alzheimer’s disease and vascular dementia were recorded, we followed the 
principal diagnosis. If both were in the additional diagnosis up to the next insurance claim in the database, the 
subject was classified as other dementia.
To evaluate the accuracy of our definition of dementia, a validation study was conducted in two teaching 
hospitals with a total of 972 patients who were given the ICD-10 codes F00, G30, F01, F02, and F03. Patient 
medical records and results of cognitive function tests including the Mini Mental State Examination of these 
patients were reviewed by three physicians. The positive predictive value was 94.7% (920/972)19.
Statistical analysis. Cox regression with separate models was used for 40–59, 60–69, and 70–79 year age 
subgroups to estimate the adjusted hazard ratio (HR) for the association between SBP level and dementia. To 
control for confounding factors, variables included age, sex, income, body mass index, alcohol consumption, 
smoking, physical activity, hypothyroidism, hyperthyroidism, major bleeding, atrial fibrillation, heart failure, 
diabetes mellitus, dyslipidemia, myocardial infarction, peripheral artery disease, chronic kidney disease, COPD, 
liver disease, malignant neoplasm, and medication at baseline (e.g. aspirin, statin, oral anticoagulant, ß-blocker, 
RAAS blocker, calcium channel blocker, diuretics and alpha blocker) were adjusted in the multivariable models. 
First, we assessed the effects of SBP measured at baseline on the risk of incident dementia. Restricted cubic spline 
curves were constructed to examine the effects of continuous values of BP. Four knots were placed at the 5th, 
35th, 65th, and 95th percentiles of BP. In addition, categorical variables of BP were used to assess associations 
with dementia. Sensitivity analysis was performed by censoring individuals at the date of incident ischemic or 
hemorrhagic stroke during follow-up because stroke could alter the risk of dementia and affect the association 
between BP and incident dementia.
During the follow-up period, BP was updated up to four times at 1–3 years interval (Fig. 2). To evaluate 
whether the increase or decrease of SBP over time could affect future risk of dementia, change of SBP was 
calculated as the difference between baseline and follow-up SBP (i.e., delta SBP). Follow-up SBP was defined 
as the earliest measured SBP that was measured 1–3 years after the initial BP measurement. To investigate the 
cumulative effects of hypertension on dementia risk, we assessed the association of each patient’s hypertension 
burden during follow-up with subsequent dementia risk. In this study, hypertension burden was defined as the 
proportion of days with increased BP (at least 140/90 mmHg) to the observation time interval, based on baseline 
and follow-up BP measurements (Fig. 2).
Descriptive statistics were used to characterize baseline characteristics and comorbidities. Continuous vari-
ables were expressed as the mean ± standard deviation (SD), and categorical variables were reported as frequency 
(percentage). Baseline characteristics were compared across the three groups using the Chi-square test or Fisher’s 
exact test for categorical variables and the ANOVA or Kruskal–Wallis test for continuous variables. Incidence 

























Hypertension burden (%) = (Days with BP ≥140/90 mmHg / Total Follow-up Days) X 100






Paent’s hypertension burden = (215+222)/(215+289+222) X 100 = 60.2%  
Figure 2.  (A) Timeline of blood pressure measurements and (B) estimation of hypertension burden during 
follow-up. BP blood pressure, FU follow-up.
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rates of dementia were calculated by dividing the number of events by person-time at risk, with the 95% con-
fidence interval (CI) estimated by exact Poisson distribution. Exact test was used in comparing two incidence 
rates. All tests were two-tailed, with P-value < 0.05 considered statistically significant. Statistical analyses were 
conducted using SAS version 9.3 (SAS Institute, Cary, NC, USA), SPSS version 23.0 statistical package (SPSS 
Inc., Chicago, IL, USA), and R statistical software, version 3.5.3 (R Foundation for Statistical Computing, Vienna, 
Austria).
Results
During the 2005–2013 period, 428,976 participants aged 40–79 years with no previous diagnosis of demen-
tia  underwent health screenings including BP measurements; 54.4% were male, and the mean age was 
55.5 ± 8.9 years. The proportions of age subgroups 40–59 years, 60–69 years, and 70–79 years were 68.3% 
(n = 292,822), 22.5% (n = 96,306), and 9.3% (n = 39,848), respectively. BP level and the proportion of comorbidi-
ties including hypertension, hyperthyroidism and atrial fibrillation were highest in population aged 70–79 years 
(Supplementary Table 2).
During the mean follow-up duration of 7.3 ± 1.5 years, 9435 dementia events were observed. The crude inci-
dence rates for dementia were 0.05 (95% confidence interval, CI 0.04–0.05), 0.51 (95% CI 0.50–0.53), 1.88 (95% 
CI 1.83–1.93) per 100 person-years in subjects 40–59, 60–69, and 70–79 years of age, respectively. The mean time 
to develop dementia was 7.4 ± 1.3, 7.1 ± 1.6 and 6.5 ± 2.0 years in age 40–59, 60–69 and 70–79 years, respectively. 
Dementia according to the time in different BP group (Supplementary Fig. 1), the number of demented patients 
per age group and types of dementia diagnosed (Supplementary Table 3) and distribution of SBP and DBP (Sup-
plementary Fig. 2) are presented in online materials. Baseline characteristics based on dementia status at the end 
of follow-up are presented in Table 1. Patients who developed dementia were older, less active, and had lower 
income and more comorbidities including heart failure and diabetes than subjects who did not develop dementia.
SBP, DBP and incidence of dementia. Among individuals with baseline SBP > 120  mmHg, contin-
uous measures of SBP using cubic splines indicated increased risk of dementia with higher SBP in subjects 
40–59 years of age (HR per 10 mmHg increase 1.22, 95% CI 1.15–1.30) and in subjects 60–69 years of age (HR 
per 10 mmHg increase 1.08, 95% CI 1.04–1.11; Fig. 3A). Significant association was not observed with SBP 
in subjects 70–79 years of age (HR per 10 mmHg increase 0.99, 95% CI 0.97–1.02). In subjects with baseline 
DBP > 80 mmHg, continuous measures of DBP using cubic splines indicated an increased risk of dementia with 
higher DBP in subjects 40–59 years of age (HR per 10 mmHg increase 1.20, 95% CI 1.10–1.30) and in subjects 
60–69 years of age (HR per 10 mmHg increase 1.07, 95% CI 1.03–1.11). Conversely, significant association was 
not observed with DBP in subjects 70–79 years of age (Fig. 3B). Similar trend was observed in subjects including 
previous history of stroke (Supplementary Fig. 3).
Even after censoring for ischemic stroke and hemorrhagic stroke, increased SBP was consistently associated 
with increased risk of dementia in subjects 40–69 years of age but not in subjects > 70 years of age (Supplementary 
Fig. 4). In analyses using SBP categories (< 120, 120–139 [reference], ≥ 140 mmHg), SBP ≥ 140 mmHg in subjects 
40–59 and 60–69 years of age was consistently associated with increased risk of dementia, with adjusted HRs of 
1.76 (95% CI 1.49–2.07) and 1.11 (95% CI 1.02–1.20), respectively (Supplementary Fig. 5).
In analyses using DBP categories (< 80 [reference], 80–90, ≥ 90 mmHg), DBP ≥ 90 mmHg in subjects 40–59 
and 60–69 years of age was consistently associated with increased risk of dementia, with adjusted HRs of 1.43 
(95% CI 1.20–1.71) and 1.16 (95% CI 1.05–1.27), respectively. (Supplementary Fig. 6).
BP and incidence of vascular and Alzheimer’s dementia. The risks of vascular and Alzheimer’s 
dementia associated with increased SBP in different age groups are shown in Fig. 4. In patients with baseline 
SBP > 120 mmHg, increasing SBP was associated with higher risk of vascular dementia in subjects 40–59 years 
of age (HR per 10 mmHg increase 1.31, 95% CI 1.18–1.45) and in subjects 60–69 years of age (HR per 10 mmHg 
increase 1.16, 95% CI 1.07–1.26; Fig. 4A). Increasing SBP was also associated with higher risk of Alzheimer’s 
dementia in subjects 50–59 years of age (HR per 10 mmHg increase 1.20, 95% CI 1.10–1.30) and in subjects 
60–69 years of age (HR per 10 mmHg increase 1.07, 95% CI 1.03–1.11; Fig. 4B). Significant associations were not 
observed between SBP and the two types of dementia in subjects 70–79 years of age.
Hypertension burden and dementia risk. Figure 5 depicts the risk of dementia associated with contin-
uous measures of hypertension burden during follow-up using restricted cubic spline analyses (burden of < 40% 
as reference). The cubic spline suggested a log-linear relationship between hypertension burden and the risk 
of dementia in those aged 40–59  years (Fig.  5A). Increase in hypertension duration continuously increased 
the adjusted risk of dementia (adjusted HR per 10% increase 1.09, 95% CI 1.08–1.10) and reached an adjusted 
HR of 2.95 (95% CI 2.23–3.91) at 100% (< 40% as reference). In patients aged 40–59 years, the association of 
hypertension burden was consistent with the risks of both dementia subtypes (Fig. 5B), more prominently for 
vascular dementia (adjusted HR 1.11, 95% CI 1.09–1.13) than for Alzheimer Dementia (adjusted HR 1.07, 95% 
CI 1.06–1.08).
BP control and incidence of dementia. Among 83,868 subjects with baseline SBP ≥ 140 mmHg, 61,678 
had follow-up BP measurements. The large positive and negative change of SBP increased the risk of all-cause 
dementia, showing a U-shaped relationship (Fig. 6A). In subjects 40–59 years, with delta SBP decreasing below 
baseline to −  25  mmHg, the spline curve indicated a decrease in risk of dementia using subjects with delta 
SBP = 0 mmHg as reference (nadir point at − 13 mmHg; HR 0.86, 95% CI 0.75–0.97). The risk of dementia 
increased as delta SBP increased from nadir point (HR per 10  mmHg increase 1.21, 95% CI 1.03–1.44). In 
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subjects 60–69 years, the risk of dementia increased as delta SBP increased over nadir point (HR per 10 mmHg 
increase 1.11, 95% CI 1.00–1.22). However, a non-significant association between delta SBP and dementia risk 
was observed among subjects ≥ 70 years of age.
The risk of dementia associated with follow-up SBP in patients with uncontrolled (≥ 140 mmHg) baseline SBP 
is shown in Fig. 6B. In patients with baseline SBP ≥ 140 mmHg, follow-up SBP 120–139 mmHg was associated 
with decreased risk of dementia compared with follow-up SBP ≥ 140 mmHg (continuously uncontrolled) in both 
Table 1.  Baseline characteristics of patients based on dementia status at the end of follow-up. Values are 
presented as mean ± standard deviation or n (%). COPD chronic obstructive pulmonary disease, RAAS renin–
angiotensin–aldosterone system.
Variables Overall (n = 428,976) No dementia (n = 419,541) Dementia (n = 9,435) p value
Age, years 55.5 ± 8.9 55.2 ± 8.7 68.4 ± 7.0 < 0.001
Male 233,380 (54.4) 229,557 (54.7) 3823 (40.5) < 0.001
Systolic blood pressure, mmHg 125.8 ± 16.6 125.7 ± 16.6 131.1 ± 18.4 < 0.001
Diastolic blood pressure, mmHg 78.4 ± 10.7 78.4 ± 10.7 79.3 ± 11.0 < 0.001
Hypertension diagnosis at baseline 126,525 (29.0) 121,369 (29.0) 5156 (55.0) < 0.001
Hypertension duration at baseline, months 3.1 ± 1.7 3.1 ± 1.7 3.2 ± 1.6 0.001
High tertile of income 237,043 (54.7) 232,311 (55.4) 4732 (50.2) < 0.001
Body mass index, kg/m2 24.0 ± 2.9 24.0 ± 2.9 23.6 ± 3.1 < 0.001
Alcohol consumption, times/week < 0.001
< 1 288,206 (73.3) 280,998 (73.1) 7208 (81.9)
1–2 64,669 (16.4) 63,952 (16.6) 717 (8.1)
3–4 25,523 (6.5) 25,131 (6.5) 392 (4.5)
≥ 5 15,030 (3.8) 14,545 (3.8) 485 (5.5)
Missing values 35,548 34,195 633
Smoking < 0.001
Never 290,814 (71.6) 283,677 (71.4) 7137 (80.2)
Ex 37,707 (9.3) 37,126 (9.3) 581 (6.5)
Current 77,524 (19.1) 76,348 (19.2) 1176 (13.2)
Missing values 22,931 22,390 541
Physical activity, times/week < 0.001
0–2 300,056 (76.8) 293,085 (76.8) 6971 (80.1)
3–4 48,643 (12.5) 48,047 (12.6) 596 (6.8)
≥ 5 41,842 (10.7) 40,707 (10.7) 1135 (13.0)
Missing values 38,435 37,702 733
Hypothyroidism 10,739 (2.5) 10,452 (2.5) 287 (3.0) < 0.001
Hyperthyroidism 10,670 (2.5) 10,354 (2.5) 316 (3.3) < 0.001
Major bleeding 4017 (0.9) 3838 (0.9) 179 (1.9) < 0.001
Atrial fibrillation 3754 (0.9) 3552 (0.8) 202 (2.1) < 0.001
Heart failure 12,300 (2.9) 11,438 (2.7) 862 (9.1) < 0.001
Diabetes mellitus 33,025 (7.7) 31,394 (7.5) 1631 (17.3) < 0.001
Dyslipidemia 100,786 (23.5) 97,654 (23.3) 3132 (33.2) < 0.001
Myocardial infarction 4043 (0.9) 3845 (0.9) 198 (2.1) < 0.001
Peripheral artery disease 7672 (1.8) 7357 (1.8) 315 (3.3) < 0.001
Chronic kidney disease 2957 (0.7) 2847 (0.7) 110 (1.2) < 0.001
COPD 39,440 (9.2) 37,321 (8.9) 2119 (22.5) < 0.001
Liver disease 88,432 (20.6) 85,962 (20.5) 2470 (26.2) < 0.001
Malignant neoplasm 28,304 (6.6) 27,269 (6.5) 1035 (11.0) < 0.001
Medication at baseline
Aspirin 49,560 (11.6) 47,406 (11.3) 2154 (22.8) < 0.001
Statin 40,145 (9.4) 38,831 (9.3) 1314 (13.9) < 0.001
Oral anticoagulant 1255 (0.3) 1190 (0.3) 65 (0.7) < 0.001
ß-blocker 50,899 (11.9) 48,761 (11.6) 2138 (22.7) < 0.001
RAAS blocker 52,025 (12.1) 49,927 (11.9) 2098 (22.2) < 0.001
Calcium channel blocker 66,124 (15.4) 63,389 (15.1) 2735 (29.0)  < 0.001
Diuretics 60,560 (14.1) 57,741 (13.8) 2819 (29.9) < 0.001
Alpha blocker 14,808 (3.5) 14,180 (3.4) 628 (6.7) < 0.001
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subjects 40–59 years of age (HR 0.69, 95% CI 0.50–0.95) and 60–69 years of age (HR 0.81, 95% CI 0.68–0.97). No 
significant associations between follow up SBP and dementia risk was observed among subjects ≥ 70 years of age.
An analysis of effects of different classes of antihypertensive medications on subsequent dementia risk is 
presented in Supplementary Fig. 7. There is no significant effect on the risk of dementia according to the type 
of BP medication.
Figure 3.  Adjusted HRs for risk of dementia according to baseline (A) SBP and (B) DBP measured in 
different age subgroups. Spline curves represent HRs adjusted for age, sex, income, body mass index, alcohol 
consumption, smoking, physical activity, hypothyroidism, hyperthyroidism, major bleeding, atrial fibrillation, 
heart failure, diabetes mellitus, dyslipidemia, myocardial infarction, peripheral artery disease, chronic kidney 
disease, chronic obstructive pulmonary disease, liver disease, malignant neoplasm, and medication at baseline 
(e.g. aspirin, statin, oral anticoagulant, ß-blocker, RAAS blocker, calcium channel blocker, diuretics and alpha 
blocker). Subjects with baseline SBP 120 mmHg or DBP 80 mmHg were used as reference. CI confidence 
interval, DBP diastolic blood pressure, HR hazard ratio, SBP systolic blood pressure.
Figure 4.  Adjusted HRs for risk of (A) vascular and (B) Alzheimer’s dementia according to baseline SBP 
measured in different age subgroups. Subjects with baseline SBP 120 mmHg were used as reference. Spline 
curves represent HRs adjusted same as Fig. 3. Abbreviations as in Fig. 3.
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Discussion
The present study results revealed four principal findings: (i) increased SBP and DBP were associated with 
increased dementia risk in individuals < 70 years of age but not in subjects > 70 years of age, even after censoring 
for stroke; (ii) increased hypertension burden was associated with increased risk of dementia, and this association 
was more pronounced for the risk of vascular disease; (iii) large positive and negative changes of SBP increased 
the risk of dementia in a U-shaped relationship and optimal follow-up SBP of 120–139 mmHg was associated 
with reduced dementia risk in subjects < 70 years of age. These findings provide important information regarding 
the effects of hypertension burden and optimal BP control, which has previously shown significant benefit for 
cardiovascular morbidity and mortality, on development of dementia based on age.
Current literature is unclear regarding the association between hypertension and cognitive decline or 
 dementia11. Systematic reviews have indicated that variations in age and follow-up duration contribute to the 
lack of  consensus3,20. In the present study, hypertension (baseline SBP ≥ 140 mmHg or baseline DBP ≥ 90 mmHg) 
was associated with increased risk of dementia in the general population < 70 years of age but not ≥ 70 years of 
age, which is consistent with results in numerous studies that showed midlife hypertension to be associated with 
increased dementia risk in later  life5,6.
Increased dementia risk associated with high BP was present in subjects free of stroke at baseline, even after 
censoring for future stroke. This suggests that subclinical vascular brain injury, including white matter lesions, 
microbleeds, infarcts, and dilated perivascular spaces, is an important mechanism underlying the relationship 
between hypertension and  dementia11.
In subtype analyses, the effects of hypertension were consistent with the risks of vascular and Alzheimer’s 
dementia. Although the association of high BP with vascular dementia was pronounced in previous studies, the 
association with Alzheimer’s dementia is  inconsistent21–23. However, compelling evidence shows that hyperten-
sion is associated not only with vascular dysfunction and cerebrovascular disease, but also with beta amyloid 
deposition, which is an emerging marker for risk of Alzheimer’s  dementia24–27.
There is a lack of definitive support from RCTs regarding the effectiveness of controlling hypertension for 
prevention of  dementia8–11,26,28. If hypertension is a risk factor for dementia only when present in midlife, as 
shown in this and previous studies, then preventing dementia by lowering BP would be effective only when 
initiated before 70 years of age. However, an RCT of BP intervention in these age groups would be very difficult 
because a large sample and long follow-up would be required due to the fact that most cases of incident demen-
tia occur in later  life11. In several observational and meta-analysis studies, lowering SBP has been suggested to 
reduce the risk of cognitive impairment, and the evidence is stronger for lowering BP in middle age compared 
with later in  life3,8,29. However, most observational studies regarding BP effects on dementia risk in midlife used 
a single BP measurement and provided no information regarding hypertension control between this measure-
ment and the onset of dementia. Therefore, in the present study, the effects of BP changes were investigated, and 
age-specific optimal BP levels were determined using follow-up BP measurements.
Our findings of a log-linear association of hypertension burden with dementia suggest cumulative effects of 
hypertension on cognitive function. These are consistent with the results of previous studies that have suggested 
that sustained hypertension in mid- and late-life is associated with higher risk of subsequent  dementia30,31. 
Figure 5.  (A) Hypertension burden and risk of overall dementia measured in different age subgroups 
(burden < 40% as reference) (B) Hypertension burden and risk of vascular and Alzheimer’s dementia in 
patients aged 40–59 years (burden < 40% as reference). Spline curves represent HRs adjusted same as Fig. 3. CI 
confidence interval, HR hazard ratio.
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Associations between hypertension burden and each dementia subtype have not been previously reported. In 
this study, vascular dementia risk was more strongly affected by total cumulative exposure to hypertension than 
was Alzheimer risk, suggesting adequate BP control might help minimize the risk of dementia, especially in 
patients with more vascular risk factors.
Previous studies showed that low SBP is related to risk of  dementia32,33. Low BP could result in decreased 
blood flow to the brain. In this study, a U-shaped relationship between delta SBP and the risk of dementia was 
observed. This result indicated that both excessively low and excessively high BP may fail to prevent dementia. 
Among individuals < 70 years of age, SBP of 120–139 mmHg was the optimal range for reducing risk of dementia. 
Although patients with baseline SBP < 120 mmHg did not have significantly increased risk of dementia compared 
with those with baseline SBP 120 ~ 139 mmHg, large positive and negative changes of SBP (delta SBP) were 
associated the increased risk of dementia in subjects < 70 years of age (presented in Fig. 6). The results indicate 
the appropriate target BP ranges for future trials examining reduction of BP for dementia prevention.
Limitations. This study has several limitations. First, this retrospective and non-randomized study cannot 
prove or disprove causal relationships. Studies using administrative databases might be susceptible to errors aris-
ing from coding inaccuracies. To minimize this problem, the definition previously validated in studies that used 
the Korean NHIS sample cohort was  applied16–18,34. Second, although the repeated measurements of initially 
elevated BP used in this study could reduce the risk of overestimation through an association with a median 
8 mmHg decrease in SBP (compared with initial readings)35, BP was measured at a single visit. Uniformity of 
BP measuring devices was lacking since health examinations were performed in different hospitals and clinics. 
Nevertheless, instruments for BP measurements in all health examination institutions receive quality assessment 
every 3 years according to the Basic Act on National Health  Examination15,16,18. Third, this study used the meas-
urement of BP only at the follow-up timepoints. The definition of hypertension burden assumes that the BP was 
elevated on all days between the measurements and this does not have to be true. Fourth, although patients with 
diagnosed dementia were excluded, baseline cognitive function was not assessed; thus, the influence of mild 
Baseline SBP ≥ 140 mmHg
Age categories Follow-up SBP Subjects, n Events, n Rate per 100 PY(95% CI) Adjusted HR (95% CI) P value
Age 40~59 years
<120 mmHg 3,659 21 0.08 (0.05-0.12) 1.00 (0.62-1.62) 0.99
120 ~ 139 mmHg 18,264 76 0.06 (0.04-0.07) 0.69 (0.50-0.95) 0.02
≥ 140 mmHg 13,790 82 0.08 (0.06-0.10) 1 (reference) -
Age 60 ~ 69 years
<120 mmHg 1,790 82 0.64 (0.51-0.79) 1.14 (0.88-1.48) 0.31
120 ~ 139 mmHg 7,919 270 0.47 (0.42-0.53) 0.81 (0.68-0.97) 0.02
≥ 140 mmHg 6,984 278 0.54 (0.48-0.61) 1 (reference) -
Age ≥ 70 years
<120 mmHg 1,015 117 1.70 (1.41-2.04) 1.02 (0.82-1.27) 0.86
120 ~ 139 mmHg 4,287 478 1.59 (1.45-1.74) 0.95 (0.83-1.09) 0.47
≥ 140 mmHg 3,970 461 1.66 (1.51-1.82) 1 (reference) -
0 .0 0 .5 1 .0 1 .5 2 .0
Age 60~69 yearsAge 40~59 years Age 70~79 years
(A) Delta SBP and risk of demen
a in pa
ents with uncontrolled ( 140 mmHg) baseline SBP
(B) Follow-up SBP and risk of demen
a in pa
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Figure 6.  (A) Adjusted HR for risk of dementia according to delta SBP in patients with uncontrolled 
(≥ 140 mmHg) baseline SBP. Delta SBP was defined as follow-up SBP minus baseline SBP. Subjects with delta 
SBP = 0 mmHg were used as reference. (B) Event rates and adjusted HR for risk of dementia according to 
follow-up SBP in patients with uncontrolled (≥ 140 mmHg) baseline SBP. Rates are per 100 person-years. 
Subjects with continuously uncontrolled hypertension (follow-up SBP ≥ 140 mmHg) were used as reference. 
Spline curves represent HRs adjusted same as Fig. 3. Abbreviations as in Fig. 3.
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baseline cognitive dysfunction could not be excluded or examined. Last, only Asians were enrolled in the present 
study, and it is unclear whether the results can be extrapolated to other populations. Despite these limitations, 
this study presents the largest population dataset in the literature used to investigate the association between 
optimal BP control and dementia outcome in the general population.
Conclusion
Increased SBP and DBP were associated with higher risks of dementia, although these effects might be attenu-
ated in older individuals. Cumulative hypertension burden was log-linearly associated with dementia risk, and 
adequate BP control was associated with lower risk of dementia in subjects < 70 years of age, suggesting that 
reducing the burden might help to minimize the risk of subsequent dementia in middle-aged patients.
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